Latest RVMD news and sentiment

#31—Not directional

TradingViewDirect company coverageStored article

ETFs Investing in Revolution Medicines, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revolution Medicines, Inc. For each ETF, it provides details such as market value, weight of Revolution Medicines, Inc. stock, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of market segments including total market, small-cap, mid-cap, large-cap, health care, and biotechnology.

Financial MarketsLife Sciences

Published

22 Aug 2026 21:11

News subject

Market update

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 15.9d old

Duplicates

1 consolidated

#32—Not directional

Stock TitanDirect company coverageStored article

Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade

Revolution Medicines, Inc. director Mark A. Goldsmith plans to sell 80,000 shares of common stock on August 21, 2026, with an aggregate market value of approximately $16.9 million. This planned sale is linked to the exercise of stock options. In the preceding three months, Goldsmith sold 10,020 shares on June 16, 2026, for proceeds of over $1.5 million.

FinanceLife Sciences

Published

22 Aug 2026 12:40

News subject

Market update

Why this score

Institutional or insider selling

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 16.3d old

Duplicates

1 consolidated

#33—Not directional

The Business JournalsDirect company coverageStored article

Revolution Medicines is about to double its space at a waterfront campus that once housed Google

Revolution Medicines, a fast-growing biotech company, is planning to significantly expand its Redwood City operations by doubling its space at the Pacific Shores campus, which previously housed Google. This expansion, involving a new lease for 700,000 square feet, is intended to support the commercial launch of its pancreatic cancer drug. The company has already seen nearly a fivefold growth in its Redwood City presence since 2020.

Life SciencesReal EstateTechnology

Published

21 Aug 2026 22:41

News subject

Market update

Why this score

Business expansion

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 16.9d old

Duplicates

1 consolidated

#34—Not directional

The Business JournalsDirect company coverageStored article

Revolution Medicines nears lease for 700,000-square-foot Redwood City campus

Revolution Medicines, a rapidly expanding biotech company, is reportedly close to securing a lease for a 700,000-square-foot campus in Redwood City. This new facility, previously a Google outpost, would support the company's significant growth since 2020 and its plans for the commercial launch of its pancreatic cancer drug. The move highlights the increasing demand for premium office space in Silicon Valley.

Life SciencesReal EstateTechnology

Published

21 Aug 2026 21:11

News subject

Market update

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 16.9d old

Duplicates

1 consolidated

#3540Tone

Stock TitanDirect company coverageStored article

Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144

The Rebecca Goldsmith Revocable Trust intends to sell 3,000 shares of Revolution Medicines (RVMD) common stock under Rule 144. The aggregate market value of this proposed sale is approximately $635,205.00. This filing follows a previous sale of 10,020 shares by Mark A. Goldsmith, trustee for the trust, on June 16, 2026.

FinanceFinancial MarketsLife Sciences

Published

21 Aug 2026 20:11

News subject

Market update

Why this score

Institutional or insider selling

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 33/100

30-day weight

<0.1% of the score · 17.0d old

Duplicates

1 consolidated

#36—Not directional

Stock TitanDirect company coverageStored article

Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale

Jeffrey Todd Cislini, a holder of Revolution Medicines (NASDAQ: RVMD), plans to sell up to 75,894 shares of common stock, valued at over $16 million, through Morgan Stanley Smith Barney LLC on or after August 21, 2026. The shares include those underlying restricted stock units and stock options. RVMD had 214,336,418 shares outstanding at the time of the filing.

FinanceLife Sciences

Published

21 Aug 2026 20:11

News subject

Market update

Why this score

Institutional or insider selling

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 17.0d old

Duplicates

1 consolidated

#3759Tone

BitgetDirect company coverageStored article

REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151

Bernstein has increased its target price for Revolution Medicines, Inc. (RVMD.O) to $179 from $151. This update, reported by Reuters, indicates a positive reevaluation of the company's stock outlook by the analyst firm.

Financial MarketsLife Sciences

Published

21 Aug 2026 13:09

News subject

Analyst action

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 31/100

30-day weight

0.2% of the score · 17.3d old

Duplicates

1 consolidated

#38—Not directional

TradingViewDirect company coverageStored article

Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW

This article provides financial data for Revolution Medicines, Inc. (NASDAQ:RVMDW), specifically focusing on its enterprise value to revenue forward. It appears to be a financial snapshot from TradingView, displaying key company information.

Financial MarketsLife Sciences

Published

19 Aug 2026 21:40

News subject

Earnings

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 18.9d old

Duplicates

1 consolidated

#39—Not directional

simplywall.stDirect company coverageStored article

Revolution Medicines (RVMD) Is Up 5.1% After Offloading Phase 3 Costs to BeOne Medicines

Revolution Medicines (RVMD) saw a 5.1% stock increase after partnering with BeOne Medicines. This collaboration shifts the financial burden of a global Phase 3 study for one of Revolution's RAS(ON) inhibitors to BeOne, while also granting BeOne regional commercialization rights in certain Asian markets. Despite this positive development, Revolution Medicines continues to face significant losses, emphasizing the need for their late-stage programs to gain approval and generate revenue.

EarningsFinancial MarketsLife Sciences

Published

19 Aug 2026 12:32

News subject

Earnings

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 19.3d old

Duplicates

1 consolidated

#40—Not directional

TradingViewDirect company coverageStored article

Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW

This article displays a financial metric, "Price to book forward," for Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a placeholder for financial data, indicating that there are no active trades or specific values to show at the time of publication, suggesting a focus on providing real-time financial information when available.

Financial MarketsLife Sciences

Published

19 Aug 2026 05:13

News subject

Market update

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 19.6d old

Duplicates

1 consolidated

#41—Not directional

Simply Wall StreetDirect company coverageStored article

Is Revolution Medicines (RVMD) Fully Valued After Its BeOne Collaboration Deal?

Revolution Medicines (RVMD) has gained investor attention due to a recent collaboration with BeOne Medicines, covering joint clinical studies on RAS(ON) inhibitors and exclusive development rights for BeOne in certain Asian markets. Despite strong share price momentum and a "Most Popular Narrative" suggesting RVMD is 4% overvalued at $212, Simply Wall St's DCF model indicates a deep undervaluation, with a fair value of $723.76 per share. The article highlights the contrasting valuation perspectives and advises investors to consider the underlying data and risks, such as heavy cash use and a concentrated therapeutic focus.

EarningsFinancial MarketsLife Sciences

Published

18 Aug 2026 05:11

News subject

Earnings

Why this score

Negative valuation view

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 20.6d old

Duplicates

1 consolidated

#4256Tone

Quiver QuantitativeDirect company coverageStored article

Why Revolution Medicines (RVMD) Stock Is Up Today

Revolution Medicines (RVMD) stock rose 5.5% today, primarily driven by continued investor optimism after the U.S. FDA accepted its new drug application for daraxonrasib, a treatment for previously treated metastatic pancreatic cancer. The positive movement is further supported by recent bullish analyst commentary and ongoing advancements in the company's broader RAS-targeted pipeline, suggesting a momentum-driven gain.

EarningsFinancial MarketsLife Sciences

Published

17 Aug 2026 18:40

News subject

Earnings

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 31/100

30-day weight

0.7% of the score · 21.1d old

Duplicates

1 consolidated

#43—Not directional

Investing.comDirect company coverageStored article

Revolution Medicines stock hits all-time high at 208.77 USD

Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is advancing late-stage programs in pancreatic and lung cancer, leading Guggenheim to raise its price target to $240.

EarningsFinancial MarketsLife Sciences

Published

17 Aug 2026 15:40

News subject

Earnings

Why this score

Analyst upgrade, Negative valuation view

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 21.2d old

Duplicates

1 consolidated

#4458Tone

MarketBeatDirect company coverageStored article

State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD

The State of Wyoming recently acquired 9,446 shares of Revolution Medicines, Inc. (NASDAQ:RVMD) valued at approximately $1.77 million, marking a new position in the biopharmaceutical company. This move comes as institutional investors and hedge funds collectively hold 94.34% of RVMD's stock. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating for Revolution Medicines, although the consensus price target is currently below the stock's reported trading price.

EarningsFinancial MarketsLife Sciences

Published

16 Aug 2026 11:11

News subject

Analyst action

Why this score

Institutional or insider buying

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 30/100

30-day weight

<0.1% of the score · 22.4d old

Duplicates

1 consolidated

#45—Not directional

MarketBeatDirect company coverageStored article

S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD

S&CO Inc. recently invested $6.4 million in Revolution Medicines, Inc. (NASDAQ:RVMD) by purchasing 34,171 shares, contributing to institutional ownership of 94.34%. Despite a larger-than-expected quarterly loss, analysts maintain a "Moderate Buy" rating with a consensus price target of $161.79. Insider transactions show mixed activity, with significant stock sales by directors totaling over $21 million in the last 90 days.

EarningsFinanceFinancial MarketsLife Sciences

Published

16 Aug 2026 11:11

News subject

Earnings

Why this score

Negative financial language

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 22.4d old

Duplicates

1 consolidated

#46—Not directional

Stock TitanDirect company coverageStored article

Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines

Baker Bros. Advisors LP and related entities have reported a passive ownership stake of 5.3% in Revolution Medicines, Inc. This translates to beneficial ownership of 11,443,357 shares of common stock, held through investment funds Baker Brothers Life Sciences, L.P. and 667, L.P. The filing indicates that Baker Bros. Advisors maintains sole voting and dispositive power over these shares.

FinanceLife Sciences

Published

14 Aug 2026 20:12

News subject

Deals and strategy

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 24.0d old

Duplicates

1 consolidated

#47—Not directional

Market sourceDirect company coverageStored article

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

BeOne Medicines AG and Revolution Medicines, Inc. have announced a clinical collaboration and licensing deal focused on RAS-addicted cancers. BeOne, a commercially strong company, will acquire exclusive rights in select Asian markets and fund a Phase 3 trial, while Revolution, a pre-revenue biotech, gains non-dilutive capital and execution scale. The partnership leverages BeOne's financial strength and Asian infrastructure with Revolution's pipeline of RAS(ON) inhibitors, presenting a synergistic opportunity for both.

Balance SheetBiotechClinical TrialsEarningsFinancial MarketsLife Sciences

Published

14 Aug 2026 19:09

News subject

Deals and strategy

Why this score

Dilution risk, Strategic partnership

Company focus

Shared story · 78%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 24.0d old

Duplicates

1 consolidated

#48—Not directional

Stock TitanDirect company coverageStored article

Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 13,564,149 shares, or 6.4%, of Revolution Medicines, Inc. (RVMD) common stock, according to a recent Schedule 13G/A filing. This includes 13,550,796 shares and 120,085 common stock purchase warrants, with the warrants subject to a 9.99% beneficial ownership limitation. Farallon Capital Management and several managing members share voting and dispositive power over these securities, with dividends and sale proceeds going to the Farallon Funds.

EarningsFinanceFinancial MarketsLife Sciences

Published

13 Aug 2026 21:12

News subject

Earnings

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 24.9d old

Duplicates

1 consolidated

#49—Not directional

Stock TitanDirect company coverageStored article

Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake

Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which belongs to the individual managed portfolios. No single managed portfolio holds more than five percent of Revolution Medicines' common stock.

FinanceFinancial MarketsLife Sciences

Published

13 Aug 2026 16:41

News subject

Deals and strategy

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 25.1d old

Duplicates

1 consolidated

#50—Not directional

nasdaq.comDirect company coverageStored article

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Corporate Affairs - Ryan AsayChairman and Chief Executive Officer - Mark GoldsmithChief Development Officer - Alan SandlerChief Financial Officer - Jack AndersChief Medical Officer - Wei LinChief Global Commercialization Officer - Anthony Mancini TAKEAWAYS Cash and Marketable Securities -- $3.9 billion as of June 30, 2026, including proceeds from public offerings and a royalty tranche.Public Offering Proceeds -- $2.2 billion in gross proceeds from concurrent offerings of common

CLINICAL-TRIALSClinical TrialsEARNINGSEarningsFDA-APPROVALFINANCIAL RESULTS

Published

12 Aug 2026 20:59

News subject

Earnings

Why this score

The headline reports news without a clear direction

Company focus

Shared story · 78%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 26.0d old

Duplicates

1 consolidated

#5157Tone

MarketBeatDirect company coverageStored article

Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD

Handelsbanken Fonder AB significantly increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 243.6% in the second quarter, bringing its total holdings to 212,275 shares valued at $39.8 million. Despite institutional investors owning a substantial 94.34% of the company, Revolution Medicines reported a quarterly loss that missed consensus estimates, and analysts anticipate a full-year loss of $8.65 per share. The stock opened near its 52-week high, with a "Moderate Buy" consensus rating and an average price target of $161.79, although company insiders have recently sold a considerable amount of shares.

EarningsFinancial MarketsLife Sciences

Published

12 Aug 2026 20:41

News subject

Earnings

Why this score

Institutional or insider buying

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 33/100

30-day weight

0.5% of the score · 26.0d old

Duplicates

1 consolidated

#52—Not directional

PluangDirect company coverageStored article

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines has achieved a $44.1 billion market cap, driven by its promising RAS-targeting oncology pipeline, despite having no current product revenue. The company's drug, daraxonrasib, has shown strong clinical results, particularly in improving survival for pancreatic cancer patients. This success makes Revolution Medicines a potential acquisition target for major pharmaceutical companies like Merck, Roche, and Bristol Myers Squibb, given the scarcity of advanced RAS therapies.

Financial MarketsLife SciencesMergers And Acquisitions

Published

12 Aug 2026 13:12

News subject

Deals and strategy

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 26.3d old

Duplicates

1 consolidated

#5357Tone

Simply Wall StreetDirect company coverageStored article

Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value

Revolution Medicines (RVMD) has shown strong shareholder returns over the past five years, but its current valuation appears expensive based on broader checks. The stock trades at a high Price-to-Book ratio compared to its industry and peers, suggesting it may be overvalued despite excitement around its pipeline. Investors need to consider if the oncology pipeline can justify the current premium or if the price already assumes too much future success.

EarningsFinancial MarketsLife Sciences

Published

12 Aug 2026 12:10

News subject

Earnings

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 31/100

30-day weight

0.3% of the score · 26.3d old

Duplicates

1 consolidated

#5442Tone

MarketBeatDirect company coverageStored article

Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD

Tema ETFs LLC has reduced its stake in Revolution Medicines, Inc. by 26.9%, selling 26,443 shares but still retaining 71,735 shares valued at $13.4 million. Despite this, institutional investors collectively own 94.34% of the company, and analyst sentiment remains largely positive with a "Moderate Buy" consensus rating. Recent insider transactions show significant selling activity, with insiders selling 132,497 shares worth approximately $21.5 million over the past 90 days.

EarningsFinanceFinancial MarketsLife Sciences

Published

12 Aug 2026 11:12

News subject

Earnings

Why this score

Institutional or insider selling

Company focus

Main company · 100%

How it is used

Direct company coverage

Story strength

Low · 33/100

30-day weight

0.4% of the score · 26.4d old

Duplicates

1 consolidated

#55—Not directional

finance.yahoo.comDirect company coverageStored article

Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Revolution Medicines has delivered a very large 5 year return that leaves the stock looking expensive on Simply Wall St's valuation checks. The current move is now being judged as richly priced rather than a clear bargain. Revolution Medicines has returned about 7x over 5 years, which puts extra focus on whether recent enthusiasm has moved the share price ahead of fundamentals. Recent interest around the company's RAS(ON) inhibitors, including the BeOne Medicines collaboration and

BiotechClinical TrialsFourth QuarterShare PriceValuation

Published

12 Aug 2026 09:11

News subject

Earnings

Why this score

The headline reports news without a clear direction

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 26.4d old

Duplicates

2 consolidated

#56—Not directional

24/7 Wall St.Direct company coverageStored article

Why Revolution Medicines May Be Big Pharma’s Next Takeover Target

Revolution Medicines (NASDAQ:RVMD) is highlighted as a potential acquisition target for big pharma due to its strong late-stage RAS(ON) oncology pipeline, particularly daraxonrasib's impressive pancreatic cancer data. Merck (NYSE:MRK) is identified as the most likely acquirer, driven by the impending patent cliff for its drug Keytruda and its stated goal of diversifying its growth portfolio. Other plausible acquirers include Pfizer, Johnson & Johnson, Bristol Myers Squibb, and Roche, but Merck has the strongest motive and means.

BALANCE SHEETBIOTECHBalance SheetBiotechFDA-APPROVALFda Approval

Published

12 Aug 2026 07:00

News subject

Deals and strategy

Why this score

Positive financial language

Company focus

Shared story · 78%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 26.5d old

Duplicates

2 consolidated

#57—Not directional

finance.yahoo.comDirect company coverageStored article

Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors, alongside a regional licensing deal granting BeOne exclusive development and commercialization rights in select Asian markets and responsibility for funding a global Phase 3 trial. This arrangement gives Revolution Medicines access to BeOne's development "superhighway," milestone and royalty potential, and externally funded late-stage development, which could influence how investors view the risk, co

BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEARNINGSEarnings

Published

12 Aug 2026 06:14

News subject

Earnings

Why this score

Negative analyst concern, Strategic partnership

Company focus

Shared story · 78%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 26.6d old

Duplicates

2 consolidated

#5859Tone

finance.yahoo.comDirect company coverageStored article

Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Revolution Medicines (RVMD) just entered a comprehensive partnership with BeOne Medicines that combines joint clinical development work and a regional rights deal in select Asian markets for its RAS(ON) oncology inhibitors. See our latest analysis for Revolution Medicines. The BeOne Medicines partnership lands at a time when Revolution Medicines has already seen strong momentum, with a 90 day share price return of 37.09% and year to date share price retu

BALANCE SHEETBIOTECHBalance SheetBiotechDISCOUNTED CASH FLOWDiscounted Cash Flow

Published

12 Aug 2026 02:35

News subject

Deals and strategy

Why this score

Positive financial language

Company focus

Shared story · 78%

How it is used

Direct company coverage

Story strength

Low · 31/100

30-day weight

0.5% of the score · 26.7d old

Duplicates

1 consolidated

#5963Tone

finance.yahoo.comDirect company coverageStored article

Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?

Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more than 400% over the past year, the question is whether this partnership adds real fuel or just more expectations to live up to.Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? Bull Case: A Partner That Shares The Load The collaboration works on two tracks. First, a clinical partnership will

BIOTECHBiotechCLINICAL-TRIALSCOLLABORATIONClinical TrialsCollaboration

Published

11 Aug 2026 20:44

News subject

Deals and strategy

Why this score

Large positive market reaction, Positive market reaction, Strategic partnership

Company focus

Shared story · 78%

How it is used

Direct company coverage

Story strength

Medium · 37/100

30-day weight

0.9% of the score · 27.0d old

Duplicates

1 consolidated

#60—Not directional

Pharmaceutical ExecutiveDirect company coverageStored article

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

BeOne Medicines and Revolution Medicines have announced a multi-part collaboration to evaluate drug combinations for RAS-addicted cancers and extend the geographic footprint of Revolution Medicines' therapies. The deal includes a clinical collaboration for combination studies using BeOne's oncology assets and Revolution's four RAS(ON) inhibitors, along with a regional rights agreement for select Asian markets. BeOne will fund a global Phase III study and Revolution Medicines will receive development and sales milestone payments, plus tiered royalties.

Life SciencesMergers And Acquisitions

Published

11 Aug 2026 13:53

News subject

Deals and strategy

Why this score

Strategic partnership

Company focus

Main company · 100%

How it is used

Shown as company news · not used in the score

Story strength

Not directional

30-day weight

None · 27.3d old

Duplicates

1 consolidated